Effect of orlistat on LIVER fat content in obese subjects with NAFLD and High concEntrAtion of pLasma proneurotensin THrough inhibition of neurotensin secretion and action

Conditions

Non-Alcoholic Fatty Liver Disease

Brief summary

The primary outcome is the treatment group difference in 6-month change (LFC% at week 24 – LFC% week -1) of absolute LFC%

Detailed description

Between group (orlistat vs control) difference of 24-week change in body weight, Between group (orlistat vs control) difference of 24-week change in insulin sensitivity (assessed by the “Homeostatic Model Assessment of insulin resistance”, “HOMA-IR”), Between group (orlistat vs control) difference of 24-week change in fasting plasma glucose., Between group (orlistat vs control) difference of 24-week change in plasma glucose 2-hours after a 75 gram oral glucose load, Between group (orlistat vs control) difference of 24-week change in plasma triglycerides, Between group (orlistat vs control) difference of 24-week change in plasma LDL-cholesterol, Between group (orlistat vs control) difference of 24-week change in systolic blood pressure, Between group (orlistat vs control) difference of 24-week change in HDL-cholesterol

Related papers

No related papers found yet.

Interventions

DRUGOrlistat STADA 120 mg hårda kapslar

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The primary outcome is the treatment group difference in 6-month change (LFC% at week 24 – LFC% week -1) of absolute LFC%	—

Secondary

Measure	Time frame
Between group (orlistat vs control) difference of 24-week change in body weight, Between group (orlistat vs control) difference of 24-week change in insulin sensitivity (assessed by the “Homeostatic Model Assessment of insulin resistance”, “HOMA-IR”), Between group (orlistat vs control) difference of 24-week change in fasting plasma glucose., Between group (orlistat vs control) difference of 24-week change in plasma glucose 2-hours after a 75 gram oral glucose load, Between group (orlistat vs control) difference of 24-week change in plasma triglycerides, Between group (orlistat vs control) difference of 24-week change in plasma LDL-cholesterol, Between group (orlistat vs control) difference of 24-week change in systolic blood pressure, Between group (orlistat vs control) difference of 24-week change in HDL-cholesterol	—

Measure

Time frame

Between group (orlistat vs control) difference of 24-week change in body weight, Between group (orlistat vs control) difference of 24-week change in insulin sensitivity (assessed by the “Homeostatic Model Assessment of insulin resistance”, “HOMA-IR”), Between group (orlistat vs control) difference of 24-week change in fasting plasma glucose., Between group (orlistat vs control) difference of 24-week change in plasma glucose 2-hours after a 75 gram oral glucose load, Between group (orlistat vs control) difference of 24-week change in plasma triglycerides, Between group (orlistat vs control) difference of 24-week change in plasma LDL-cholesterol, Between group (orlistat vs control) difference of 24-week change in systolic blood pressure, Between group (orlistat vs control) difference of 24-week change in HDL-cholesterol

—

Countries

Sweden

Outcome results

None listed